KMPH KEMPHARM INC

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by KemPharm, Inc. and Certain Officers and Directors

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky, LLP announces that it has commenced an investigation of KemPharm, Inc. (“KemPharm” or the “Company”) (NASDAQ: KMPH) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On April 16, 2015, KemPharm sold 5.09 million shares in its Initial Public Offering, raising $60 million in new capital. Then on May 5, 2016, KemPharm announced that two committees of the U.S. Food and Drug Administration had determined that one of the Company’s drugs, Apadaz, should be approved for its proposed indication of the management of acute pain that requires an opiod, but voted against inclusion of abuse-deterrent labeling for the product. Following this news, KemPharm’s stock fell 56% to close at $6.91 per share on May 6. 2016. Since the IPO, KemPharm’s stock has fallen from a high of $23.63 per share in September of 2015 to a close of $3.50 per share on October 25, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/kempharm-kmph

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
01/11/2016

Underlying

KMPHKEMPHARM INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on KEMPHARM INC

 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics Begins Trading as ZVRA

Zevra Therapeutics Begins Trading as ZVRA Company’s common stock will begin trading on the Nasdaq Global Select Market under the new ticker symbol “ZVRA” starting today, March 1, 2023 New Company name, Zevra, is Greek for zebra, the internationally recognized symbol for the rare disease community CELEBRATION, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, announced today that it will begin trading under the new ticker symbol “ZVRA” on the Nasdaq Global Selec...

March 1, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as ...

Zevra Therapeutics Reiterates Commitment to Rare Disease Community as New Corporate Council Member of the National Organization for Rare Disorders (NORD) CELEBRATION, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that it has become a Corporate Council member of the National Organization for Rare Disorders (NORD) and reiterated its commitment to the rare disease community by celebrating Rare Disease Day 2023. A rare disease is a condition that im...

February 28, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Prelimi...

Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company” and formerly known as KemPharm, Inc.), today announced it has filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”), which is scheduled to take place on April 25, 2023. Stockholders do not need to take any action with respect to the 2023 Annual Meeting at this...

February 27, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results

Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results CELEBRATION, Fla., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that the Company will host a conference call and live audio webcast on Tuesday, March 7, 2023, at 8:30 a.m. ET, to discuss its corporate and financial results for the fourth quarter and full-year 2022. The audio webcast with a slide presentation will be accessible via the Investor Relations section of the Company’s website, ....

February 27, 2023 1 EN
 PRESS RELEASE
Free
KMPH KEMPHARM INC

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Post...

Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium™ 2023 Interim data analysis of four-year, open-label extension from Phase 2/3 clinical trial suggests arimoclomol may reduce long-term progression of Niemann-Pick Disease Type C (NPC) CELEBRATION, Fla., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: KMPH) (“Zevra” or the “Company,” formerly known as KemPharm, Inc.), today announced that arimoclomol, the Company’s orally-delivered, first-in-class investigational product candidate being developed a...

February 24, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch